New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
09:17 EDTBRCM, BIIB, KING, REPYY, ISRG, DOW, TLM, WHR, JNPR, ALTR, BA, GSK, XLNX, PBYI, PEP, MCDOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Intuitive Surgical (ISRG), up 12.8%... Biogen (BIIB), up 8%... Broadcom (BRCM), up 3.6%... PepsiCo (PEP), up 1.8%... Dow Chemical (DOW), up 1.5%. ALSO HIGHER: Puma Biotechnology (PBYI), up 275% after reporting positive top line results from Phase III PB272 trial, price target on stock raised to $325 from $125 at UBS, Citigroup says company a likely acquisition target after data... Talisman Energy (TLM), up 9.6% after Bloomberg reports Repsol (REPYY) may be looking to acquire. DOWN AFTER EARNINGS: Whirlpool (WHR), down 4.4%... Juniper Networks (JNPR), down 7.9%... GlaxoSmithKline (GSK), down 5.8%... Boeing (BA), down 0.8%. ALSO LOWER: Xilinx (XLNX), down 14.2% after results, downgrades at William Blair, BofA/Merrill and BMO Capital. Shares of peer Altera (ALTR) are also down 4.6%... King Digital (KING), down 2.7% after downgraded at BofA/Merrill... McDonald's (MCD), down 0.9% following downgrades at multiple firms after its earnings report yesterday.
News For PBYI;BA;MCD;XLNX;ALTR;PEP;GSK;JNPR;WHR;ISRG;BIIB;TLM;REPYY;BRCM;DOW;KING From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 19, 2015
16:34 EDTBAAir Lease delivers one Boeing 737-800 to American Airlines
Subscribe for More Information
13:30 EDTXLNXOptions with increasing put volume;
Subscribe for More Information
10:14 EDTKINGOptions with decreasing implied volatility
Options with decreasing implied volatility: KING SUNE YY JCP URBN NTES DKS DANG SINA KSS
09:33 EDTBAActive equity options trading on open
Active equity options trading on open: AAPL BAC FB BA TWTR NFLX WMT BABA
06:12 EDTMCDStarbucks K-cup momentum is accelerating, says UBS
UBS analyst Keith Siegner says Starbucks (SBUX) is seeing accelerating momentum in the single-serve cup category. The company's K-cup sales increased 36% year-over-year for the four-week period ended August 8, according to Nielsen (NLSN), Siegner tells investors in a research note. Starbucks' K-cup promotion levels ticked up sequentially, but remain well below levels from earlier in the year, the analyst points out. The company's K-Cup portfolio continues to gain share despite increasing price pressure and new market entrants like Dunkin' Brands (DNKN) and McDonald's (MCD), Siegner writes. He keeps a Buy rating on Starbucks with a $63 price target. The stock closed yesterday up 9c to $57.83. Shares of Keurig Green Mountain (GMCR) are down 62% year-to-date in part due to the company's slowing sales in the single-serve cup category.
August 18, 2015
12:52 EDTWHRWhirlpool jumps after appliance shipments rise 11.2% in July
Subscribe for More Information
10:13 EDTKINGOptions with decreasing implied volatility
Subscribe for More Information
09:04 EDTJNPRJuniper selected by Joe Gibbs Racing to speed data center network transformation
Juniper Networks announced that four-car NASCAR team Joe Gibbs Racing selected its next-generation switching and security solutions to rev up the team's aging network infrastructure for better performance on and off the track.
08:21 EDTBIIBBiogen long-term outlook still positive, says RBC Capital
Subscribe for More Information
07:11 EDTXLNXXilinx dvices selected by Open-Source Virtual Reality Consortium
Subscribe for More Information
07:05 EDTBIIBBiogen, ALS Association, Columbia collaborate to drive understanding of ALS
Biogen, the ALS Association and Columbia University Medical Center announced a new collaboration to better understand the differences and commonalities in the ALS disease process and how genes influence the clinical features of the disease. The project, "Genomic Translation for ALS Clinical care", will involve a combination of next generation genetic sequencing and detailed clinical phenotyping in 1500 people with ALS. The goal of the project is to provide a basis for the development of precision medicine, or more individually tailored therapies for ALS. "We want to bring genomics right to the point of care in ALS where instead of focusing on retrospective DNA samples with limited clinical information, we focus on patients who are under active clinical management," said ALS Association Chief Scientist Lucie Bruijn, Ph.D., M.B.A. "By focusing on patients seen by participating ALS clinics, this project will allow investigators to ask how different genetic causes of ALS translate into different clinical consequences."
06:16 EDTMCDFast food chains making new push with more fresh ingredients, WSJ says
Subscribe for More Information
06:03 EDTBABoeing's test flight of aerial refueling tanker to be delayed, WSJ reports
Subscribe for More Information
August 17, 2015
12:41 EDTXLNXXilinx August calls active
Xilinx August 44 and 45 calls are active on total call volume of 13,600 contracts (550 puts). August call option implied volatility is at 29, September is at 33; compared to its 52-week range of 18 to 42. Active call volume suggests traders taking positions for price movement for this company that has been subject to takeover speculation.
12:38 EDTXLNXXilinx did not cancel from bus tour, Bloomberg reports
Subscribe for More Information
10:55 EDTBRCMOptions with increasing implied volatility
Subscribe for More Information
10:21 EDTKINGOptions with decreasing implied volatility
Subscribe for More Information
07:46 EDTREPYYEnerCom to hold a conference
Subscribe for More Information
07:03 EDTBIIBBiogen: Clinical data supports long-term safety, efficacy of Alprolix
New clinical data support the long-term safety and efficacy of ALPROLIX in people with severe hemophilia B treated for up to two years, Biogen announced. Participants in the Phase 3, open-label extension study, B-YOND, maintained low bleeding rates with one to two week prophylaxis regimens, according to data from an interim analysis. Investigators presented these interim results for the first time at the 67th Annual Meeting for the National Hemophilia Foundation in Dallas. B-YOND is a multi-year study for people with severe hemophilia B who completed the Phase 3 pivotal B-LONG or Kids B-LONG studies. In this interim analysis, the median time on ALPROLIX during B-YOND was 27.6 months for adults and adolescents, and 47.7 weeks for children under age 12. The study's primary endpoint is inhibitor development, and no inhibitors have been reported to-date. There were three prophylactic dosing options for adult, adolescent, and pediatric participants in the B-YOND trial - weekly, individualized, and modified prophylaxis. An episodic treatment arm was also available for adult and adolescent patients.
August 16, 2015
18:56 EDTMCDU.S. food chains see opportunity in a weakened Brazil, WSJ says
North American food chains including McDonald's (MCD), Dunkin' Brands (DNKN), Domino's Pizza (DPZ), Papa John's (PZZA), and Bloomin' Brands (BLMN) are expanding into Brazil in hopes to capture market share while local restaurants pull back amid the country's economic uncertainty, reports the Wall Street Journal. Brazilian economic troubles "make it more challenging, but it's also an opportunity... The Brazilian economy will improve, and we'll be in a position to take advantage of that," commented Patrick Murtha, president of the international arm of Bloomin' Brands. Reference Link
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use